ATE307203T1 - Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma - Google Patents

Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma

Info

Publication number
ATE307203T1
ATE307203T1 AT96929657T AT96929657T ATE307203T1 AT E307203 T1 ATE307203 T1 AT E307203T1 AT 96929657 T AT96929657 T AT 96929657T AT 96929657 T AT96929657 T AT 96929657T AT E307203 T1 ATE307203 T1 AT E307203T1
Authority
AT
Austria
Prior art keywords
interleukin
antibody
asthma
medication
producing
Prior art date
Application number
AT96929657T
Other languages
German (de)
English (en)
Inventor
Roy Clifford Levitt
W Lee Maloy
Prasad U Kari
Nicolas Nicolaides
Original Assignee
Genaera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaera Corp filed Critical Genaera Corp
Application granted granted Critical
Publication of ATE307203T1 publication Critical patent/ATE307203T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5425—IL-9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT96929657T 1995-08-24 1996-08-23 Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma ATE307203T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US276595P 1995-08-24 1995-08-24
US2380096P 1996-08-06 1996-08-06
PCT/US1996/012757 WO1997008321A1 (en) 1995-08-24 1996-08-23 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders

Publications (1)

Publication Number Publication Date
ATE307203T1 true ATE307203T1 (de) 2005-11-15

Family

ID=26670837

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96929657T ATE307203T1 (de) 1995-08-24 1996-08-23 Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
AT05009688T ATE484294T1 (de) 1995-08-24 1996-08-23 Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05009688T ATE484294T1 (de) 1995-08-24 1996-08-23 Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen

Country Status (10)

Country Link
EP (3) EP0846173B1 (enExample)
JP (3) JP3948495B2 (enExample)
AT (2) ATE307203T1 (enExample)
AU (1) AU6895696A (enExample)
CA (2) CA2230240C (enExample)
DE (2) DE69635305T2 (enExample)
DK (2) DK1632248T3 (enExample)
ES (2) ES2354360T3 (enExample)
PT (1) PT1632248E (enExample)
WO (1) WO1997008321A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830454A (en) * 1996-08-30 1998-11-03 Ludwig Institute For Cancer Research Method for treating cell mediated autoimmune disorders using interleukin-9
AU746595B2 (en) * 1996-12-02 2002-05-02 Genaera Corporation IL-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders
EP1471144B1 (en) * 1996-12-02 2010-06-23 Genaera Corporation Biological variability of asthma associated factor AAF2 (IL-9 receptor) useful in treating and diagnosing atopic allergies including asthma and related disorders
AU5532098A (en) * 1996-12-20 1998-07-17 Magainin Pharmaceuticals, Inc. A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
EP1015492A2 (en) * 1997-09-19 2000-07-05 Magainin Pharmaceuticals Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
JP2001517682A (ja) * 1997-09-19 2001-10-09 マガイニン ファーマシューティカルズ インク． 喘息および関連疾患を含むアトピー性アレルギーを治療するための標的としての喘息関連因子
CA2370821A1 (en) * 1999-05-01 2000-11-09 Genaera Corporation Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
US20040219149A1 (en) * 2001-06-08 2004-11-04 Yuhong Zhou Methods for the modulation of il-13
WO2001059142A1 (en) * 2000-02-09 2001-08-16 Medimmune, Inc. Antibody gene therapy with adeno-associated viral vectors
WO2002068594A2 (en) * 2001-02-22 2002-09-06 The Research Foundation Of State University Of New York Opiate receptors
AU2004229527B2 (en) * 2003-04-11 2009-08-20 Medimmune, Llc Methods of preventing or treating respiratory conditions
US7470521B2 (en) 2004-07-20 2008-12-30 Critical Therapeutics, Inc. RAGE protein derivatives
US7635754B2 (en) * 2004-09-22 2009-12-22 Aerovance, Inc. Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
US8354106B2 (en) 2005-06-16 2013-01-15 The Feinstein Institute For Medical Research Antibodies against HMGB1 and fragments thereof
WO2008039941A2 (en) 2006-09-27 2008-04-03 The Government Of The Usa As Represented By The Secretary Of The Dpt. Of Health And Human Services Scgb3a2 as a growth factor and anti-apoptotic agent
JP5564167B2 (ja) * 2008-05-22 2014-07-30 日本たばこ産業株式会社 苦味マスキング剤及び苦味低減方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208218A (en) * 1988-09-19 1993-05-04 Ludwig Institute For Cancer Research T cell growth factor glycoproteins
US5414071A (en) 1989-05-23 1995-05-09 Genetics Institute, Inc. Human cytokine IL-9
US5132109A (en) * 1990-10-05 1992-07-21 Ludwig Institute For Cancer Research Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof
AU2237395A (en) 1994-03-30 1995-10-23 University Of Maryland At Baltimore Human interleukin variants generated by alternative splicing

Also Published As

Publication number Publication date
ES2249786T3 (es) 2006-04-01
DK1632248T3 (da) 2011-01-24
EP2241329A2 (en) 2010-10-20
AU6895696A (en) 1997-03-19
EP1632248B8 (en) 2010-12-29
JPH11514851A (ja) 1999-12-21
EP0846173A1 (en) 1998-06-10
DK0846173T3 (da) 2006-01-16
JP2007169287A (ja) 2007-07-05
EP0846173B1 (en) 2005-10-19
JP2011152135A (ja) 2011-08-11
CA2666298A1 (en) 1997-03-06
DE69635305T2 (de) 2006-07-06
EP1632248A1 (en) 2006-03-08
CA2230240C (en) 2009-08-18
PT1632248E (pt) 2010-12-28
ES2354360T3 (es) 2011-03-14
WO1997008321A1 (en) 1997-03-06
JP4813380B2 (ja) 2011-11-09
DE69635305D1 (de) 2006-03-02
JP3948495B2 (ja) 2007-07-25
ATE484294T1 (de) 2010-10-15
DE69638281D1 (de) 2010-11-25
EP1632248B1 (en) 2010-10-13
CA2230240A1 (en) 1997-03-06
EP2241329A3 (en) 2011-03-09

Similar Documents

Publication Publication Date Title
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
ATE256475T1 (de) Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
ATE342728T1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
ATE212375T1 (de) Modifizierter ciliary neurotrophic factor (cntf), und verfahren zu dessen herstellung und verwendung
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69736183D1 (de) Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
DE69636085D1 (de) Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington&#39;s Chorea
DE59109222D1 (de) Verwendung des Wirkstoffs Flupirtin zur Herstellung eines Arzneimittels zur Bekämpfung von Muskelverspannungen
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
ATE246518T1 (de) Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
DE69233725D1 (de) Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren
ATE289816T1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer&#39;s krankheit
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE3768150D1 (de) Verwendung eines 1,3-oxazolidin-2-on-derivates zur herstellung eines arzneimittels zur behandlung von ischaemie.
DE69719930D1 (de) Verfahren zur Herstellung von medizinischen Pflastern zur perkutanen Verabreichung, und Vorrichtung dafür
DE69720064D1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE69915848D1 (de) Verwendung von neohesperidin dc zur herstellung eines medikaments zur vorbeugung bzw. behandlung von krankheiten aufgrund erhoehter blutfettwerte
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE69424415D1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0846173

Country of ref document: EP